Pretreatment with melatonin exerts anti-inflammatory effects against ischemia/reperfusion injury in a rat middle cerebral artery occlusion stroke model

Journal of Pineal Research

Volumn 37, Issue 2, 2004, Pages 85-91

  Pei, Zhong ^a   Cheung, Raymond Tak Fai ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cerebral ischemia; Cyclooxygenase 2; Glial fibrillary acidic protein; Inflammation; Ischemia reperfusion injury; Melatonin; Myeloperoxidase; Neuronal nitric oxide synthase

Indexed keywords

CYCLOOXYGENASE 2; GLIAL FIBRILLARY ACIDIC PROTEIN; MELATONIN; MYELOPEROXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; BRAIN PROTECTION; BRAIN TISSUE; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; HEART RATE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; RAT; REPERFUSION INJURY; SINGLE DRUG DOSE;

ANIMALS; ANTIOXIDANTS; BRAIN; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOHISTOCHEMISTRY; INFARCTION, MIDDLE CEREBRAL ARTERY; ISOENZYMES; MALE; MELATONIN; NEURONS; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; PEROXIDASE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY;

EID: 4344600602     PISSN: 07423098     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2004.00138.x     Document Type: Article

References (50)

1. CHEUNG RT. The utility of melatonin in reducing cerebral damage resulting from ischemia and reperfusion. J Pineal Res 2003; 34:153-160.
2. PASCHEN W. Role of calcium in neuronal cell injury: which subcellular compartment is involved? Brain Res Bull 2000; 53:409-413.
3. CHAN PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 2001; 21:2-14.
4. IADECOLA C, ALEXANDER M. Cerebral ischemia and inflammation. Curr Opin Neurol 2001; 14:89-94.
5. PETTY MA, WETTSTEIN JG. Elements of cerebral microvascular ischaemia. Brain Res Rev 2001; 36:23-34.
6. EMERICH DF, DEAN RL III, BARTUS RT. The role of leukocytes following cerebral ischemia: pathogenic variable or bystander reaction to emerging infarct? Exp Neurol 2002; 173:168-181.
7. LEKER RR, SHOHAMI E. Cerebral ischemia and trauma - different etiologies yet similar mechanisms: neuroprotective opportunities. Brain Res Rev 2002; 39:55-73.
8. SAMDANI AF, DAWSON TM, DAWSON VL. Nitric oxide synthase in models of focal ischemia. Stroke 1997; 28:1283-1288.
9. IADECOLA C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci 1997; 20:132-139.
10. CHEN SH, FUNG PC, CHEUNG RT. Neuropeptide Y-Y1 receptor modulates nitric oxide level during stroke in the rat. Free Rad Biol Med 2002; 32:776-784.
11. LANGENBACH R, MORHAM SG, TIANO HF et al. Cyclooxygenase knockout mice: models for elucidating isoform-specific functions. Biochem Pharmacol 1999; 58:1237-1246.
12. CHEUNG RT, PEI Z, FENG ZH et al. Cyclooxygenase-1-gene knockout does not alter middle cerebral artery occlusion in a mouse stroke model. Neurosci Lett 2002; 330:57-60.
13. GOVONI S, MASOERO E, FAVALLI L et al. The cyclooxygenase-2 inhibitor SC58236 is neuroprotective in an in vivo model of focal ischemia in the rat. Neurosci Lett 2001; 303:91-94.
14. IADECOLA C, NIWA K, NOGAWA S et al. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA 2001; 98:1294-1299.
15. STOLL G, JANDER S, SCHROETER M. Inflammation and glial responses in ischemic brain lesions. Prog Neurobiol 1998; 56:149-171.
16. ASCHNER M. Astrocytic functions and physiological reactions to injury: the potential to induce and/or exacerbate neuronal dysfunction - a forum position paper. Neurotoxicology 1998; 19:7-17.
17. BROWN DR. Neurons depend on astrocytes in a coculture system for protection from glutamate toxicity. Mol Cell Neurosci 1999; 13:379-389.
18. CHEN Y, VARTIAINEN NE, YING W et al. Astrocytes protect neurons from nitric oxide by a glutathione-dependent mechanim. J Neurochem 2001; 77:1601-1610.
19. MAKAROV PR, WISWEDEL I, AUGUSTIN W et al. Hypoxia/reoxygenation-induced damage to mitochondrial activity is determined by glutathione threshold in astroglia-rich cell cultures. Brain Res 2002; 933:91-97.
20. TAN DX, CHEN LD, POEGGELER B et al. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocrine J 1993; 1:57-60.
21. REITER R, TANG L, GARCIA JJ et al. Pharmacological actions on melatonin in oxygen radical pathophysiology. Life Sci 1997; 60:2255-2271.
22. REITER RJ. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 1998; 56:359-384.
23. PEI Z, Ho HT, CHEUNG RT. Pre-treatment with melatonin reduces volume of cerebral infarction in a permanent middle cerebral artery occlusion stroke model in the rat. Neurosci Lett 2002; 318:141-144.
24. PEI Z, PANG SF, CHEUNG RT. Pretreatment with melatonin reduces volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. J Pineal Res 2002; 32:168-172.
25. PEI Z, PANG SF, CHEUNG RT. Administration of melatonin after onset of ischemia reduces the volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. Stroke 2003; 34:770-775.
26. PEI Z, FUNG PC, CHEUNG RT. Melatonin reduces nitric oxide level during ischemia but not blood-brain-barrier breakdown during reperfusion in a rat middle cerebral artery occlusion stroke model. J Pineal Res 2003; 34:110-118.
27. PEI Z, CHEUNG RT. Melatonin protects SHSY5Y neuronal cells but not cultured astrocytes from ischemia due to oxygen and glucose deprivation. J Pineal Res 2003; 34:194-201.
28. LONGA EZ, WEINSTEIN PR, CARLSON S et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20:84-91.
29. CHEN SH, CHEUNG RT. Peripheral and central administration of neuropeptide Y in a rat middle cerebral artery occlusion stroke model reduces cerebral blood flow and increases infarct volume. Brain Res 2002; 927:138-143.
30. CHEN SH, CHEUNG RT. Intracerebroventricular injection of a neuropeptide Y-Y1 receptor agonist increases while BIBP3226, a Y1 antagonist, reduces the infarct volume following transient middle cerebral artery occlusion in rats. Neuroscience 2003; 116:119-126.
31. ZHANG ZG, CHOPP M, GAUTAM S et al. Upreguation of neuronal nitric oxide synthase and mRNA, and selective sparing of nitric oxide synthase-containing neurons after focal cerebral ischemia in rat. Brain Res 1994; 654:85-95.
32. NOGAWA S, ZHANG F, Ross ME et al. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997; 17:2746-2755.
33. CHEUNG RT, CECHETTO DF. Colchicine affects cortical and amygdalar neurochemical changes differentially after middle cerebral artery occlusion in rats. J Comp Neurol 1997; 387:27-41.
34. CHEUNG RT, CECHETTO DF. Neuropeptide Y-Y1 receptor antisense oligodeoxynucleotide increases the infarct volume after middle cerebral artery occlusion in rats. Neuroscience 2000; 98:771-777.
35. LIN B, GINSBERG MD, BUSTO R et al. Hyperglycemia triggers massive neutrophil deposition in brain following transient ischemia in rats. Neurosci Lett 2000; 278:1-4.
36. POZO D, REITER RJ, CALVO JR et al. Inhibition of cerebellar nitric oxide synthase and cyclic GMP production by melatonin via complex formation with calmodulin. J Cell Biochem 1997; 65:430-442.
37. NOGAWA S, FORSTER C, ZHANG F et al. Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia. Proc Natl Acad Sci USA 1998; 95:10966-10971.
38. CUZZOCREA S, COSTANTINO G, MAZZON E et al. Regulation of prostaglandin production in carrageenan-induced pleurisy by melatonin. J Pineal Res 1999; 27:9-14.
39. CUZZOCREA S, MAZZON E, SERRAINO I et al. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J Pineal Res 2001; 30:1-12.
40. MOHAN N, SADEGHI K, REITER RJ et al. The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappa B. Biochem Mol Biol Int 1995; 37:1063-1070.
41. CHUANG JI, MOHAN N, MELTZ ML et al. Effect of melatonin on NF-kappa-B DNA-binding activity in the rat spleen. Cell Biol Int 1996; 20:687-692.
42. GILAD E, WONG HR, ZINGARELLI B et al. Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFκκB activation. FASEB J 1998; 12:685-693.
43. LEZOUALC'H F, SPARAPANI M, BEHL C. N-acetyl-serotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-kappaB. J Pineal Res 1998; 24:168-178.
44. SUGIMOTO K, IADECOLA C. Delayed effect of administration of COX-2 inhibitor in mice with acute cerebral ischemia. Brain Res 2003; 960:273-276.
45. GUPTA YK, CHAUDHARY G, SINHA K. Enhanced protection by melatonin and meloxicam combination in a middle cerebral artery occlusion model of acute ischemic stroke in rat. Can J Physiol Pharmacol 2002; 80:210-217.
46. MATSUO Y, ONODERA H, SHIGA Y et al. Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Effects of neutrophil depletion. Stroke 1994; 25:1469-1475.
47. PANTONI L, SARTI C, INZITARI D. Cytokines and cell adhesion molecules in cerebral ischemia: experimental bases and therapeutic perspectives. Arterioscler Thromb Vasc Biol 1998; 18:503-513.
48. BARONE FC, HILLEGASS LM, TZIMAS MN et al. Time-related changes in myeloperoxidase activity and leukotriene B4 receptor binding reflect leukocyte influx in cerebral focal stroke. Mol Chem Neuropathol 1995; 24:13-30.
49. ALLEGRA M, FURTMULLER PG, REGELSBERGER G et al. Mechanism of reaction of melatonin with human myeloperoxidase. Biochem Biophys Res Commun 2001; 282:380-386.
50. BORLONGAN CV, YAMAMOTO M, TAKEI N et al. Glial cell survival is enhanced during melatonin-induced neuroprotection against cerebral ischemia. FASEB J 2000; 14:1307-1317.